Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience

Basit Öğe Kaydı
dc.authorid0000-0001-6732-8068
dc.authorid0000-0003-1508-2822
dc.authorid0000-0002-9005-5587
dc.authorid0000-0003-4766-1861
dc.authorid0000-0002-2035-9462
dc.authorid0000-0001-9636-4113
dc.contributor.authorYiğit Kaya, Süreyya
dc.contributor.authorMutlu, Yaşa Gül
dc.contributor.authorMalkan, Ümit Yavuz
dc.contributor.authorMehtap, Özgür
dc.contributor.authorKeklik Karadağ, Fatma
dc.contributor.authorKorkmaz, Gülten
dc.contributor.authorElverdi, Tuğrul
dc.contributor.authorSaydam, Güray
dc.contributor.authorÖzet, Gülsüm
dc.contributor.authorAr, Muhlis Cem
dc.contributor.authorMelek, Elif
dc.contributor.authorMaral, Senem
dc.contributor.authorKaynar, Leylagül
dc.contributor.authorSevindik, Ömür Gökmen
dc.date.accessioned2024-05-10T13:10:17Z
dc.date.available2024-05-10T13:10:17Z
dc.date.issued2024
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractBackground: Hairy cell leukemia (HCL) is a rare mature B-cell malignancy that is primarily treated with purine analogues. However, relapse remains a significant challenge, prompting the search for alternative therapies. The BRAF V600E mutation prevalent in HCL patients provides a target for treatment with vemurafenib. Patients and methods: This multicenter retrospective study included nine patients with relapsed/refractory (R/R) HCL from six different centers. Patient data included demographics, prior treatments, clinical outcomes, and adverse events. Results: Patients received different treatment regimens between centers, including vemurafenib alone or in combination with rituximab. Despite the differences in protocols, all patients achieved at least a partial response, with seven patients achieving a complete response. Adverse events were generally mild with manageable side effects. The absence of myelotoxic effects and manageable side effects make BRAF inhibitors attractive, especially for patients ineligible for purine analogues or those with severe neutropenia. Conclusion: Single agent vemurafenib or in combination with rituximab appears to be a promising therapeutic option for R/R HCL. Further research is needed to establish standardized treatment protocols and to investigate long-term outcomes.
dc.identifier.citationYiğit Kaya, S., Mutlu, Y. G., Malkan, Ü. Y., Mehtap, Ö., Keklik Karadağ, F., Korkmaz, G. ... Sevindik, Ö. G. (2024). Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience. Leukemia Research, 140. http://dx.doi.org/10.1016/j.leukres.2024.107495
dc.identifier.doi10.1016/j.leukres.2024.107495
dc.identifier.issn0145-2126
dc.identifier.pmid38599153
dc.identifier.scopus2-s2.0-85189889806
dc.identifier.scopusqualityQ2
dc.identifier.urihttp://dx.doi.org/10.1016/j.leukres.2024.107495
dc.identifier.urihttps://hdl.handle.net/20.500.12511/12443
dc.identifier.volume140
dc.identifier.wos001225444600001en_US
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorYiğit Kaya, Süreyya
dc.institutionauthorMutlu, Yaşa Gül
dc.institutionauthorMelek, Elif
dc.institutionauthorMaral, Senem
dc.institutionauthorKaynar, Leylagül
dc.institutionauthorSevindik, Ömür Gökmen
dc.language.isoen
dc.relation.ispartofLeukemia Researchen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectBRAF Inhibitor
dc.subjectHairy Cell Leukemia
dc.subjectRituximab
dc.subjectVemurafenib
dc.titleSingle agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Yiğit Kaya-Süreyya-2024.pdf
Boyut:
384.01 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu